PF-06412562 is under clinical development by Cerevel Therapeutics Holdings and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect PF-06412562’s likelihood of approval (LoA) and phase transition for Parkinson’s Disease took place on 01 Jul 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their PF-06412562 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

PF-06412562 overview

PF-06412562 is under development for the treatment of Parkinson's disease. The drug candidate is a new molecular entity (NME). The drug candidate is administered through oral route as a tablet. It acts by targeting dopamine receptor 1. It was also under development for cognitive disorders and schizophrenia.

Cerevel Therapeutics Holdings overview

Cerevel Therapeutics Holdings (Cerevel Therapeutics) is a biopharmaceutical company. It develops and commercializes medicines for the treatment of central nervous system (CNS) disorders. Cerevel Therapeutics is headquartered in Boston, Massachusetts, United States.

Quick View PF-06412562 LOA Data

Report Segments
  • Innovator
Drug Name
  • PF-06412562
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.